Search by drug, manufacturer, or indication

Displaying 1021 - 1030 of 1165

Iclusig (ponatinib)

Status:

Concluded with an LOI

Manufacturer:

Paladin Labs Inc.

Indication:

Chronic Myeloid Leukemia/Acute Lymphoblastic Leukemia

Last updated July 4, 2016

Victoza (liraglutide)

Status:

Concluded without agreement

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated June 17, 2016

Jinarc (tolvaptan)

Status:

Negotiations were not pursued

Manufacturer:

Otsuka Canada Pharmaceutical Inc.

Indication:

Autosomal dominant polycystic kidney disease (ADPKD)

Last updated June 10, 2016

Cosentyx (secukinumab)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Psoriasis, moderate to severe plaque

Last updated June 8, 2016

Zydelig (idelalisib)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Chronic lymphocytic leukemia

Last updated June 3, 2016

Tafinlar/Mekinist (dabrafenib/trametinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Metastatic Melanoma

Last updated May 25, 2016

Lemtrada (alemtuzumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated May 11, 2016

Xeljanz (tofacitinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Rheumatoid Arthritis

Last updated April 26, 2016

Simponi IV (golimumab)

Status:

Concluded without agreement

Manufacturer:

Janssen Inc.

Indication:

Rheumatoid Arthritis

Last updated April 19, 2016

Tobi Podhaler (tobramycin)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Pseuodomonas aeruginosa infections in cystic fibrosis

Last updated April 19, 2016